3M Drug Delivery Systems Forms Collaboration with Presspart Group for Dose Counter Technologies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

3M Drug Delivery Systems Forms Collaboration with Presspart Group for Dose Counter Technologies


3M Drug Delivery Systems Division has announced a collaborative agreement with specialist medical device and pharmaceutical component manufacturer, Presspart Group (a division of the German-based Heitkamp & Thumann Group). Under the terms of the agreement, Presspart is licensed to sell 3M’s Dose by Dose Counter and Dose Indicator, adding to its portfolio of capabilities with metered dose inhaler (MDI) actuators.

The agreement enables both organizations the opportunity to accelerate growth of dose counter technology in existing and future MDI development, with expanded access to a range of actuator configurations.

3M Drug Delivery Systems will continue to support its customers and offer the Dose by Dose Counter and Dose Indicator to future customers as part of its end-to-end inhalation technology expertise. Both technologies are compatible with most valves, and are customizable to meet partners’ requirements. They are easy for patients to use and retain a familiar actuator look and feel.

The 3M Dose Counter technology is available for third-party developments and has been approved by FDA in conjunction with an MDI product. It notifies patients of exactly how many doses of medication they have left in their MDI and helps prevent them from running out unexpectedly, thus protecting them from an unsafe situation. It also has the potential to minimize wastage of medication, which may have a positive effect on healthcare costs.  Its clear display is easy to understand for a wide range of users, young and old, giving an incremental indication of doses remaining in the MDI.

Source: 3M Drug Delivery Systems Division 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here